NCT03383692 - Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

September 11, 2023

Conditions

Neoplasm Metastasis

Interventions

DRUG

DS-8201a

DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution

DRUG

Ritonavir

Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration

DRUG

Itraconazole

Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration

Trial Locations (10)

100

National Taiwan University Hospital, Taipei

003-0804

Hokkaido Cancer Center, Sapporo

060-8648

Hokkaido University Hospital, Sapporo

650-0017

Kobe University Hospital, Kobe

431-3125

Hamamatsu University Hospital, Hamamatsu

411-0934

Shizuoka Cancer Center, Nagaizumicho

104-0045

National Cancer Center Hospital, Chuo Ku

135-8550

The Cancer Institute Hospital of JFCR, Koto-Ku

03080

Seoul National University Hospital, Seoul

06351

Samsung Medical Center, Seoul